

GENERAL INDEX

References to individual volumes are listed before colons; numbers following a colon refer to page numbers. A **boldface** page number indicates the main essay for a topic. An *italicized* page number refers to a photo or illustration.

A

- Abdominal breathing, 2:925, 1041
Abnormal involuntary movement scale, 1:1–2
ABPN (American Board of Psychiatry and Neurology), 2:789
Abreu, Jose, 1:433
Absence seizures, 2:866, 868, 1015
Absenteeism, 1:241
Abstinence model, 1:20, 385, 2:698, 782
Abstinence syndrome, 2:697
Abstract thought, 1:277, 374, 2:1017
Abuse, 1:2–7
 bodywork therapies for, 1:138
 conduct disorder and, 1:238
 conversion disorder from, 1:243, 245
 creative therapies for, 1:251
 dissociation from, 1:321
 elder, 1:4
 emotional, 1:3–4, 6, 288–289, 377, 2:740
 physical, 1:3, 4, 288–289
 psychological, 1:3
 spouse, 1:4, 5
 See also Child abuse; Domestic violence; Sexual abuse; Substance abuse
Academic achievement. *See* Educational performance
Acamprosate, 1:34
Acceptance, 1:460
Access to care, 1:232
Accidents, automobile. *See* Motor vehicle accidents
Acetaminophen
 for Alzheimer's disease, 1:44
 caffeine and, 1:165
 for pain disorder, 2:715
 SAME and, 2:838
Acetazolamide, 1:149
Acetylcholine
 for Alzheimer's disease, 2:622
 for anxiety, 2:710
 for depression, 2:710
 for enuresis, 1:366
 for food cravings, 2:683
 for generalized anxiety disorder, 1:439
 light therapy and, 1:568
 for major depressive disorder, 2:588
 for opioid-related disorders, 2:700
 for pain disorder, 2:716
 for panic disorder, 2:710
 for smoking cessation, 2:664
 for specific phobias, 2:925
Alzheimer's disease and, 1:40, 2:659
 amantadine and, 1:46
 benztropine and, 1:116
 biperiden and, 1:126
 donepezil and, 1:335
 galantamine and, 1:424
 protriptyline and, 2:786
 rivastigmine and, 2:829
 tacrine and, 2:969
 trihexyphenidyl and, 2:1003
 Wernicke-Korsakoff syndrome and, 2:1034
Acetylcholinesterase, 1:424
Achenbach Child Behavior Rating Scales, 1:94, 2:883
Achievement, academic. *See* Educational performance
Achievement tests, 2:1036–1037
Acid. *See* Lysergic acid diethylamide (LSD)
Acquired immune deficiency syndrome (AIDS)
 dementia from, 1:278, 279, 280, 2:707–708
 interpersonal therapy for, 1:542
 marijuana for, 1:170
 self-help groups for, 2:878
 stigma against, 2:934
 suicide and, 2:960
Acrocyanosis, 1:63
Acting out, 1:221, 238
Action potentials, 1:145
Activities of daily living
 Alzheimer's disease and, 1:42
 grief and, 1:462
 group homes and, 1:464
 mental retardation and, 2:611–615
 reading disorder and, 2:814, 816
 retraining, 1:224–226
 schizophrenia and, 2:848
 somatization disorder and, 2:918, 919
Acupressure. *See* Shiatsu
Acupuncture, 1:8–13, 9, 10, 11
 for alcoholism, 1:34
 for Alzheimer's disease, 2:622
 for anxiety, 2:710
 for depression, 2:710
 for enuresis, 1:366
 for food cravings, 2:683
 for generalized anxiety disorder, 1:439
 light therapy and, 1:568
 for major depressive disorder, 2:588
 for opioid-related disorders, 2:700
 for pain disorder, 2:716
 for panic disorder, 2:710
 for smoking cessation, 2:664
 for specific phobias, 2:925
Acute pain, 1:9, 2:713, 715, 716
 See also Pain
Acute stress disorder, 1:13–17, 16, 2:940
 vs. adjustment disorder, 1:15, 22
 depersonalization and, 1:287
 dissociation and, 1:320
 vs. post-traumatic stress disorder, 1:13, 17, 446, 2:779
Acute Stress Disorder Scale, 1:15
ADA. *See* Americans with Disabilities Act
ADAM (Arrestee Drug Abuse Monitoring), 1:215
Adaptation, 1:308
Adaptive skills, 2:612–615
Addams, Jane, 2:915
Addiction, 1:18–20, 2:952–953
 amphetamine, 1:57, 58, 60
 benzodiazepine, 1:300
 caffeine, 1:165, 168
 cannabis, 1:170, 171, 172–173
 cocaine, 1:212–213, 215, 217, 218
 denial and, 1:283
 desipramine for, 1:293
 disease concept of, 1:18, **317–318**
 endorphins and, 2:659
 gambling, 2:737–739
 genetic factors and, 1:318
 hallucinogen, 1:480
 heroin, 1:212, 218, 540
 hypnotherapy for, 1:295, 508

- impulse-control disorders and, 1:523
- inhalant, 1:525, 526, 527, 528, 529
- Internet, 1:**537–539**
- interpersonal therapy for, 1:540
- lorazepam, 1:574
- naltrexone for, 2:641
- neurotransmitters and, 1:296, 2:659
- nicotine, 2:661, 663, 952
- opioid, 2:696, 697, 698, 699–700
- panic disorder and, 2:719
- pemoline, 2:745
- phencyclidine, 2:755
- polysubstance, 1:299, 2:**770–771**
- process of, 1:296, 537
- relapse, 2:819, 821
- reward systems and, 1:296
- schizophrenia and, 2:849
- sedative, 2:863–865
- to self-help groups, 2:879
- self-help groups for, 1:20, 2:876–879
- sexual dysfunctions, 2:879
- shopping, 1:538
- Substance Abuse Subtle Screening Inventory for, 2:954
- substituting, 2:879
- support groups for, 2:965–966
- token economy system for, 2:989
- treatment of, 1:544
- urine tests for, 2:1009
- zaleplon, 2:1045
- See also* Alcoholism; Substance abuse; Twelve step programs
- Addiction Potential Scale, 2:625
- Adenosine receptors, 1:166
- Adipex-P. *See* Phentermine
- Adipose tissue, 2:679–684
- ADIS (Anxiety Disorders Interview Scale), 2:779, 923
- ADIS-C (Anxiety Disorders Interview Scale for Children), 2:908
- Adjustment disorder, 1:**20–24**
- acute stress disorder and, 1:15, 22
- depression and, 1:21, 22, 292
- vs. post-traumatic stress disorder, 1:22, 2:778
- stress and, 1:21, 22–23, 24, 2:940
- Adler, Alfred, 1:468, 2:709
- Adlerian therapy, 2:647
- Adolescents
- addiction and, 1:20
- adjustment disorder in, 1:23–24
- aggression in, 2:985
- amphetamines and, 1:59–60
- anorexia nervosa in, 1:60–64
- antidepressants for, 1:542–543
- Asperger's disorder and, 1:84
- autism and, 1:102
- body dysmorphic disorder in, 1:134, 135
- bulimia nervosa and, 1:154, 155, 159–160
- cannabis and, 1:171–172, 173
- case management for, 1:177
- cigarette smoking by, 2:662–663
- cocaine and, 1:218
- conduct disorder in, 1:237
- cyclothymic disorder in, 1:261
- depression in, 1:185
- with dual diagnosis, 1:339
- explosive behavior in, 2:985
- family education and, 1:394
- intelligence tests for, 1:553–555, 2:1030
- interpersonal therapy for, 1:542–543
- Kaufman Short Neurological Assessment Procedure for, 1:556–558
- major depressive disorder in, 2:583, 586
- multisystemic therapy for, 2:636–640
- neglected, 2:654
- obsessive-compulsive disorder in, 2:689
- oppositional defiant disorder in, 2:703
- pedophilia and, 2:741
- peer groups and, 2:743–745
- phencyclidine and, 2:755
- premature ejaculation in, 2:782
- prescription drug abuse by, 1:66
- psychoanalysis for, 2:791
- pyromania in, 2:802–804, 805
- schizotypal personality disorder in, 2:860
- seasonal affective disorder in, 2:862
- selective mutism in, 2:870
- separation anxiety disorder in, 2:881
- sleep terror disorder in, 2:902
- social phobia in, 2:905–907, 908, 909–910
- specific phobias in, 2:920, 925
- stereotypic movement disorder in, 2:931, 932
- stuttering in, 2:949
- Substance Abuse Subtle Screening Inventory for, 2:954
- suicidal behavior in, 2:744, 961
- suicide by, 2:586
- temper tantrums in, 2:985
- tic disorders in, 2:985
- transvestic fetishism in, 2:991
- trichotillomania in, 2:999
- voyeurism in, 2:1024
- Adoption studies (Genetic), 1:447
- Adrenal gland disorders, 2:708
- Adrenaline, 2:660
- Adult abuse, 1:4, 6–7
- Advance directives, 1:**24–25**, 548–549, 2:622
- Advertising, 1:134
- Advocacy, 1:547, 2:878
- Aerobic exercise, 1:402
- Affect, 1:**25–26**
- assessment of, 1:92, 450
- blunted, 1:26, 2:850, 855
- dysthymic disorder and, 1:76, 344
- histrionic personality disorder and, 1:496
- Affective disorders. *See* Mood disorders
- African Americans
- Alzheimer's disease and, 2:934
- body dysmorphic disorder in, 1:135
- bulimia nervosa in, 1:157
- cigarette smoking by, 2:662–663
- generalized anxiety disorder in, 1:437
- hypertension in, 2:946
- Kaufman Short Neurological Assessment Procedure and, 1:558
- masculinity and, 1:433
- panic disorder in, 2:720
- social phobia in, 2:908
- specific phobias in, 2:922
- stigmatization of, 2:935
- stroke in, 2:945, 946, 948
- Aftercare groups, 2:821
- Age-associated memory impairment, 1:279, 2:655
- Agent-driven directives, 1:25
- Aggression
- in adolescents, 2:985
- Alzheimer's disease and, 1:42
- assertiveness training and, 1:88, 89
- causes of, 2:709
- cognitive problem-solving skills training for, 1:221
- conduct disorder and, 1:237, 238, 238
- Diagnostic and Statistical Manual of Mental Disorders* on, 1:308
- impulsive, 1:534–536
- obsessive, 2:688
- paranoid personality disorder and, 2:726
- in peer groups, 2:743–744
- pyromania and, 2:802
- social phobia and, 2:907
- Thematic Apperception Test for, 2:974
- See also* Passive-aggressive behavior
- Aging
- cognitive retraining for, 1:224–226
- erectile dysfunction and, 1:368
- fear of, 1:202
- female sexual arousal disorder and, 1:410
- loss and, 1:459
- memory loss and, 2:939

- narcissistic personality disorder and, 2:648
 respite care and, 2:822
 schizophrenia and, 2:848
 stigmatization of, 2:935
 support groups for, 2:965
 women and, 1:433
See also Elderly
- Agitation**
 Alzheimer's disease and, 1:42, 44
 brief psychotic disorder and, 1:153
 delusional disorder and, 1:272
 fluphenazine for, 1:416–417
 haloperidol for, 1:272
 lorazepam for, 1:272
 schizoaffective disorder and, 2:841
 thioridazine for, 2:978
 thiothixene for, 2:980–982
 trifluoperazine for, 2:1001–1003
- Agnosia**, 1:41, 277
- Agoraphobia**, 1:26–30, 2:720
 bibliotherapy for, 1:119
 exposure treatment for, 1:28, 29, 382
 genetic factors in, 1:26–27, 446, 2:720, 906
 guided imagery for, 1:472
 with panic attacks, 1:26, 228
 with panic disorder, 1:26, 71, 2:717–722, 923
 social phobia and, 1:26, 28, 2:906
 tic disorders and, 2:987
 tranylcypromine for, 2:993
 treatment of, 2:721
- Agoraphobic Self-Statements Questionnaire**, 1:29
- Agranulocytosis**, 1:130, 210, 211, 2:852
- AHPA (American Herbal Products Association)**, 1:458, 559
- AIDS**. *See* Acquired immune deficiency syndrome
- Akathisia**
 beta blockers for, 1:117–118
 from mesoridazine, 2:617
 neuroleptic-induced, 2:603, 605, 606
 tardive, 2:971
- Akinesia**, 1:180, 181, 2:636
- Alanine**, 1:444
- Al-Anon**. *See* Alcoholics Anonymous
- Alateen**, 2:877
- Alcohol**
 anxiety disorder and, 2:955–957
 barbiturates and, 1:110
 breathing-related sleep disorder and, 1:149
 cannabis and, 1:172
 chloral hydrate and, 1:193
 chlorpromazine and, 1:196
 clomipramine and, 1:204
 clonazepam and, 1:206
 clorazepate and, 1:209
 clozapine and, 1:211
 cocaine and, 1:212
 counselors, 1:546
 delirium and, 1:268
 desipramine and, 1:295
 detoxification, 1:295, 297
 diazepam and, 1:310, 311
 diphenhydramine and, 1:317
 doxepin and, 1:338
 erectile dysfunction and, 1:369
 estazolam and, 1:372
 fluoxetine and, 1:415
 flurazepam and, 1:419
 in foods, 1:315
 gabapentin and, 1:423
 haloperidol and, 1:482
 imipramine and, 1:521, 522
 insomnia and, 1:531
 intermittent explosive disorder and, 1:536
 kava kava and, 1:560
 lorazepam and, 1:574
 maprotiline and, 2:598
 mesoridazine and, 2:617
 methadone and, 2:619
 mirtazapine and, 2:627
 molindone and, 2:634
 narcolepsy and, 2:650
 nefazodone and, 2:652
 nortriptyline and, 2:669
 olanzapine and, 2:696
 oxazepam and, 2:712
 paranoia and, 2:723
 phenelzine and, 2:758
 pimozide and, 2:765
 propranolol and, 2:785
 protriptyline and, 2:786, 787
 psychotic disorder from, 2:957–958
 quazepam and, 2:807, 808
 quetiapine and, 2:809
 SAME and, 2:838
 temazepam and, 2:972, 974
 thioridazine and, 2:979
 thiothixene and, 2:982
 for tic disorders, 2:982
 tranylcypromine and, 2:994, 995
 trazodone and, 2:997
 triazolam and, 2:997
 trifluoperazine and, 2:1002
 valerian and, 2:1015
 venlafaxine and, 2:1020
 zaleplon and, 2:1045
 zolpidem and, 2:1048, 1049
See also Alcohol abuse; Alcoholism
- Alcohol abuse**, 1:19, 30–35
 bibliotherapy for, 1:119
 biofeedback for, 1:122
 citalopram for, 1:200
 diagnosis of, 1:19
 hallucinogens and, 1:480
 intermittent explosive disorder and, 1:535
 with mental disorders, 1:339–340
- polysubstance dependence and, 2:771
 post-traumatic stress disorder and, 2:778
 relapse, 2:820
 social phobia and, 2:904, 906
 social skills training for, 2:911, 912
 in veterans, 2:778
See also Alcohol withdrawal; Alcoholism
- Alcohol withdrawal**, 1:31, 32, 33–34
 alprazolam for, 1:35
 chlordiazepoxide for, 1:193
 clonidine for, 1:206–207
 clorazepate for, 1:208
 delirium from, 1:266, 268
 diazepam for, 1:297, 309
 diet and, 1:313
 hallucinations from, 1:475
 oxazepam for, 2:710–712
 panic attacks from, 2:720
 stress and, 2:940
 symptoms of, 1:296–297
- Alcoholic psychoses**, 1:19
- Alcoholics**, children of, 1:339
- Alcoholics Anonymous**, 1:20, 34, 299, 545, 2:876–877, 965
- Alcohol-induced amnesic disorders**, 1:50, 51, 52, 2:1032, 1034
- Alcoholism**, 1:19, 30–35
 adjustment disorder and, 1:23
 amnesic disorders from, 1:50, 51, 52, 2:1032, 1034
 aversion therapy for, 1:104–105
 biofeedback for, 1:122
 chlordiazepoxide for, 1:193, 297
 dementia from, 1:275, 279
 denial and, 1:283
 diagnosis of, 1:33, 2:899
 disease model of, 1:18, 317–318
 disulfiram for, 1:19, 34, 332–333
 executive function and, 1:375
 exposure treatment for, 1:384–385
 gamma-aminobutyric acid and, 2:659
 gender differences in, 1:19
 histrionic personality disorder and, 1:497
 mental disorders from, 2:710
 mesoridazine for, 2:616–617
 naltrexone for, 1:34, 2:641
 neurotransmitters and, 1:18, 32, 2:659
 nutrition deficiency from, 2:670, 672
 person-centered therapy for, 2:751
 self-help groups for, 1:34, 2:876–877
 suicide and, 2:960
 tic disorders from, 2:987
 treatment of, 1:300, 332–333
 twelve step programs for, 1:30, 299, 545, 2:876–877, 879, 965